Leucovorin (also called folinic acid, calcium folinate, or citrovorum factor) is a reduced, already-active form of folate (vitamin B9). It is used as a prescription medicine, not as a general vitamin supplement.
Unlike ordinary folic acid, it does not need conversion by the enzyme dihydrofolate reductase (DHFR). That is why it can work when that enzyme is blocked.
Main medical uses
- Methotrexate rescue: After high-dose methotrexate (common in osteosarcoma and some other cancers), or when methotrexate is not clearing properly, or after overdose of methotrexate or other folate antagonists (e.g., pyrimethamine, trimethoprim). It “rescues” healthy cells so they can keep making DNA while the chemotherapy still affects cancer cells.
- With 5-fluorouracil (5-FU): In advanced colorectal cancer (and some other GI cancers), leucovorin increases 5-FU’s effect on thymidylate synthase, making the chemo more potent. This also increases toxicity to healthy tissues.
- Folate-deficiency megaloblastic anemia when oral folic acid cannot be used.
- Cerebral folate transport deficiency (FOLR1-CFTD): A rare genetic condition in which folate cannot reach the brain properly. This can cause developmental delay, seizures, movement problems, and autism-like features. The FDA has added this indication based on a literature review of case reports. It is not approved as a general treatment for autism.
Off-label uses have included certain other cancers, methanol poisoning (as a cofactor), and prevention of hematologic toxicity from pyrimethamine in some settings.
How it differs from folic acid
Folic acid is a synthetic, oxidized precursor that must be reduced by DHFR. Leucovorin is already in a usable reduced form (5-formyl-THF), so it bypasses that step and can enter cells even when DHFR is inhibited. High-dose folic acid is not a substitute for leucovorin in methotrexate rescue or FOLR1-CFTD.
Administration and practical notes
It is given by mouth (tablets), intramuscularly, or intravenously. Oral absorption is saturable above about 25 mg, so higher rescue doses usually require injection. Dosing is highly protocol-specific and timed relative to methotrexate levels or 5-FU.
Side effects and cautions
Leucovorin itself is generally well tolerated. Allergic reactions (rash, urticaria, rare anaphylaxis) can occur. When combined with 5-FU, common effects include nausea, vomiting, diarrhea, stomatitis (mouth sores), fatigue, and myelosuppression—these are largely driven by the intensified 5-FU.
Important warnings:
- It is not appropriate for pernicious anemia or other B12-deficiency anemias; blood counts may improve while neurologic damage continues.
- It can reduce the effectiveness of methotrexate if given at the wrong time.
- It may increase seizure frequency in some patients on certain anticonvulsants.
- It should be started promptly after methotrexate overdose or delayed clearance.
Leucovorin is not an approved or established treatment for autism in general. It is approved for a very rare genetic condition that can look like autism in some people, and it has been studied off-label in a subset of autistic children. The evidence for broad use is weak.
What the FDA actually approved
In 2026 the FDA expanded the label of leucovorin (folinic acid) tablets for cerebral folate transport deficiency caused by a confirmed variant in the FOLR1 gene (CFD-FOLR1). That disorder is ultra-rare (on the order of 1 in a million). People with it can have low folate in the brain, developmental delay, seizures, movement problems, and autism-like features. Case-report reviews suggested many of those patients improved on oral leucovorin. That is not an approval for autism as a diagnosis.
Earlier public comments that it would become available “for children with autism” went further than the evidence supported. The agency later stated there was not enough data for a broader autism indication.
Why people talk about it in autism
The idea is that some autistic children have folate receptor-alpha autoantibodies (FRAA) that block folate transport into the brain, producing a form of cerebral folate deficiency even when blood folate is normal. Leucovorin can use an alternate transporter (the reduced folate carrier) and may raise brain folate in that setting.
Some studies have reported FRAA in a substantial fraction of autistic children, but that finding is not uniformly accepted as causal for typical autism, and antibody positivity does not automatically mean low CSF folate.
What the trials show
Small randomized and open-label studies (together only a few hundred children) have reported improvements in language, communication, or behavior in some participants—often more clearly in those who were FRAA-positive. Effects are not universal; some children do not respond.
Limitations that professional groups emphasize:
Small samples, mixed methods, and outcomes that are not always pre-registered or corrected for multiple comparisons
One of the larger trials was later retracted over data and analysis problems
Another trial had serious monitoring/compliance issues
Safety data at the high doses used (often ~1–2 mg/kg/day, up to tens of milligrams) are still limited compared with oncology use
Results do not generalize to “autism” as a whole
The American Academy of Pediatrics and the Child Neurology Society do not recommend routine leucovorin for autistic children without a confirmed folate-transport disorder. They call for larger, rigorous trials.
Practical takeaway
Confirmed FOLR1-related CFD: leucovorin is an indicated treatment for the metabolic problem (which may include autism-like symptoms).
Autistic child without that genetic diagnosis: this is off-label, experimental, and not standard care. Testing (FRAA, sometimes CSF 5-MTHF) and a trial of treatment, if considered at all, belong with a specialist who can weigh benefits, side effects, drug supply, and established therapies (behavioral interventions, speech therapy, etc.).
Over-the-counter folic acid is not a substitute for prescription leucovorin in this context.
Prescriptions rose sharply after 2025 media and political attention even though the evidence for typical autism did not change. That does not make it first-line treatment. Any decision should be made with a clinician who knows the child’s full medical picture—not from headlines.
This is background information only. Dosing, timing, and whether leucovorin is appropriate must be determined by a physician who knows the patient’s diagnosis, lab values (especially methotrexate levels), and other medications.
deemagclinic
deemag and chest clinic 